Servier's $1.5B bet on Edgewise drug fails five months in

The muscular dystrophy drug that Servier bought for $1.55 billion upfront has already failed its pivotal trial. The drug, called sevasemten, failed the primary and secondary endpoints in the GRAND CANYON pivotal ...